Clinical development plan: 9-cis-retinoic acid.
D000077556:Alitretinoin; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D005260:Female; D006801:Humans; D009374:Neoplasms, Experimental / Q000517:prevention & control; D051381:Rats; D012107:Research Design; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D000077556:Alitretinoin; D014212:Tretinoin